Nerve Growth Factor Market

DelveInsight’s “Nerve growth factor (NGF) – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Nerve growth factor, historical and forecasted epidemiology as well as the Nerve growth factor market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Nerve growth factor market report provides current treatment practices, emerging drugs, the Nerve growth factor market share of individual therapies, and current and forecasted Nerve growth factor market size from 2019 to 2032, segmented by the seven major markets. The report also covers current Nerve growth factor treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study period: 2019–2032

Nerve growth factor Understanding and Treatment Algorithm

The DelveInsight’s Nerve growth factor market report gives a thorough understanding of the Nerve growth factor by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Nerve growth factor, a neurotrophin, modulates a diverse set of physiologic processes in the nervous, immune, and endocrine systems. It is the first-discovered member of the neurotrophin family, that is involved in neural development, differentiation, and maintenance of neurons in the peripheral nervous system (PNS) and the functional integrity of cholinergic neurons in the central nervous system (CNS), not only during development but also during adulthood. It is recognized as a pleiotropic factor and is produced and utilized by several cell types, including structural, accessory, and immune cells.

The biological action of Nerve growth factor is mediated by two nerve growth factor receptors, the historically recognized high-affinity receptor trkANGFR, having a tyrosine kinase activity, and the low-affinity transmembrane glycoprotein, a non-selective pan-neurotrophin receptor p75NTR that regulates signaling through trkANGFR . The binding of nerve growth factor to p75NTR activates additional signaling pathways that in the absence or reduced expression of co-expressed trkANGFR on nerve growth factor-target cells trigger apoptosis. The effect of nerve growth factor on target cells depends on the ratio of these two receptors co-distributed on the cell surface.

The reduced transport of nerve growth factor, produced by nerve growth factor targets or innervated tissues leads to damage to nerve cells, as observed in peripheral neuropathies. The level of expression of nerve growth factor and its receptor has a significant correlation with the proliferation, differentiation, and migration of tumor cells in various cancers. It is also a key mediator involved in peripheral pain.

 

Nerve growth factor diagnosis

Nerve growth factors can be measured in saliva. Historically, the method for measuring saliva nerve growth factor involves the off-label use of an enzyme immunoassay designed for use with cell-culture supernatants/tissue extracts. Further, mature or biologically active beta-nerve growth factor serum levels can be measured with a double antibody sandwich enzyme-linked immunosorbent assay (ELISA).

 

Nerve growth factor treatment

Nerve growth factor has great pharmacological potential, for the treatment of major central neurodegenerative diseases and peripheral neuropathies. There are multiple indications where the therapeutic potential of nerve growth factors is being evaluated for the treatment of patients. They are being developed as potential drugs to combat acute and chronic neurodegenerative processes. Further, various anti-nerve growth factor agents either alone or in combination are being given to treat conditions associated with abnormal nerve growth factors.

Nerve growth factor Epidemiology

The Nerve growth factor epidemiology section provides insights into historical and current Nerve growth factor patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Nerve growth factor report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

 

Key findings

According to Zhao et al. (2022), Osteoarthritis (OA) is the third leading cause of disability, affecting approximately 350 million people worldwide. The nerve growth factor is associated with pain signal transduction and nociceptor receptor gene expression, it is a nociceptor sensitizer and was studied as a potential alternative target for the treatment of pain in OA. According to the study, the risk for rapidly progressive OA at final follow-up ranged from 0.7% to 6.3% for anti-NGF monoclonal antibody treatment and from 0.2% to 1.2% for the active comparator (4.4% vs 0.8% overall).

The Nerve growth factor epidemiology covered in the report provides historical as well as forecasted nerve growth factor epidemiology [segmented as Prevalence of Disease Causing Nerve Damage, Diagnosed Prevalence of Disease Causing Nerve Damage, Number of Cases Treated in Different Disease Causing Nerve Damage, and Number of Cases Treated with Nerve growth factor in Different Disease Causing Nerve Damage] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Country-wise Nerve growth factor Epidemiology

The epidemiology segment also provides the Nerve growth factor epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan

 

Nerve growth factor Drug Chapters

The drug chapter segment of the Nerve growth factor report encloses a detailed analysis of Nerve growth factor marketed drugs and late-stage (Phase III and Phase II) Nerve growth factor pipeline drugs. It also helps understand the Nerve growth factor clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging Nerve growth factor drugs

The report details the emerging Nerve growth factor therapies under the late and mid-stage of development for Nerve growth factor treatment.

Nerve growth factor Market Outlook

The Nerve growth factor market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Nerve growth factor market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Nerve growth factor market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Nerve growth factor market in the 7MM is expected to witness a major change in the study period 2019–2032.

 

Key findings

This section includes a glimpse of the Nerve growth factor market in the 7MM.

 

The United States: Nerve growth factor Market Outlook

• This section provides the total Nerve growth factor market size and market size by therapies in the United States.

 

EU4 and the United Kingdom: Nerve growth factor Market Outlook

• The total Nerve growth factor market size and market size by therapies in EU4 (Germany, France, Italy, and Spain) and the United Kingdom are provided in this section.

 

Japan: Nerve growth factor Market Outlook

• The total Nerve growth factor market size and market size by therapies in Japan are also mentioned.

 

Nerve growth factor Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Nerve growth factor market or expected to get launched in the market during the study period 2019–2032. The analysis covers Nerve growth factor market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This will help in understanding the Nerve growth factor drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

Nerve growth factor Pipeline Development Activities

The report provides insights into different therapeutic candidates in the Phase II, and Phase III stages. It also analyses the Nerve growth factor’s key players involved in developing targeted therapeutics.

 

Nerve growth factor market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Nerve growth factor emerging therapies.

 

Nerve growth factor Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Nerve growth factor domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Nerve growth factor market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Nerve growth factor market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• Descriptive overview of Nerve growth factor, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Nerve growth factor epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Nerve growth factor, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Nerve growth factor market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based market forecasting determines the trends shaping and driving the global Nerve growth factor market

 

Report Highlights

• In the coming years, the Nerve growth factor market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Nerve growth factor R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
• Major players are involved in developing Nerve growth factor therapies. The launch of emerging therapies will significantly impact the Nerve growth factor market
• A better understanding of Nerve growth factor pathogenesis will also contribute to the development of novel therapeutics for Nerve growth factor
• Our in-depth analysis of the Nerve growth factor pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Nerve growth factor Report Insights

• Patient-Based Market Forecasting
• Therapeutic approaches
• Nerve growth factor pipeline analysis
• Nerve growth factor market size and trends
• Nerve growth factor market opportunities
• Impact of upcoming therapies

 

Nerve growth factor Report Key Strengths

• 11 years forecast
• The 7MM Coverage
• Nerve growth factor epidemiology segmentation
• Key cross competition
• KOL views
• Nerve growth factor drugs uptake

 

Nerve growth factor Report Assessment

• Current treatment practices
• Unmet needs
• Nerve growth factor pipeline product profiles
• Nerve growth factor market attractiveness

 

Key Questions

Nerve growth factor market insights:

• What would be the Nerve growth factor market growth till 2032, and what will be the resultant market size in 2032?
• What was the Nerve growth factor drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Nerve growth factor total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across the 7MM, and which country will have the largest Nerve growth factor market size during the forecast period (2019–2032)?
• How would the unmet needs affect the Nerve growth factor market dynamics and subsequent analysis of the associated trends?

 

Nerve growth factor Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Nerve growth factor?
• What is the historical and forecasted Nerve growth factor patient pool in the 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Nerve growth factor in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Nerve growth factor therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nerve growth factor and its status, along with the challenges faced?

 

Reasons to Buy

• The patient-based market forecast analysis will help in developing business strategies by understanding trends shaping and driving the Nerve growth factor market
• Organize sales and marketing efforts by identifying the best opportunities for Nerve growth factor in the US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors